We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+11.2%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.54B
AUM Growth
+$718M
Cap. Flow
-$27.8M
Cap. Flow %
-0.29%
Top 10 Hldgs %
34.85%
Holding
152
New
15
Increased
35
Reduced
32
Closed
15

Top Buys

Rank Stock Value
1
CI icon
Cigna
CI
+$196M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$129M
3
GILD icon
Gilead Sciences
GILD
+$84.7M
4
VTRS icon
Viatris
VTRS
+$64.4M
5
BIIB icon
Biogen
BIIB
+$51.1M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$118M
2
PFE icon
Pfizer
PFE
+$98M
3
HCA icon
HCA Healthcare
HCA
+$97.1M
4
THC icon
Tenet Healthcare
THC
+$94.8M
5
AGN.PRA
Allergan plc
AGN.PRA
+$73.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.6%
2 Financials 1.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IART icon
76
Integra LifeSciences
IART
$1.38B
$23.3M 0.24%
+426,910
New +$20.4M
OBSV
77
DELISTED
ObsEva SA Ordinary Shares
OBSV
$22.3M 0.23%
2,605,531
– –
LKFT
78
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$21.7M 0.23%
283,500
– –
ASMB icon
79
Assembly Biosciences
ASMB
$494M
$18.3M 0.19%
74,036
-30,739
-29% -$8.66M
DBVT
80
DBV Technologies
DBVT
$797M
$18.3M 0.19%
51,290
– –
SVA
81
DELISTED
Sinovac Biotech, Ltd
SVA
$18M 0.19%
2,667,500
– –
TEVA icon
82
Teva Pharmaceuticals
TEVA
$40.5B
$17.5M 0.18%
526,300
+113,700
+28% +$3.52M
CTIC
83
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$16.6M 0.17%
+5,000,000
New +$19.5M
VNDA icon
84
Vanda Pharmaceuticals
VNDA
$298M
$15.8M 0.17%
967,859
+917,659
+1,828% +$13.2M
XNCR icon
85
Xencor
XNCR
$1.48B
$15.8M 0.17%
747,244
-92,993
-11% -$2.08M
JAZZ icon
86
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
$15.6M 0.16%
+100,000
New +$15.3M
CHRS icon
87
Coherus Oncology
CHRS
$219M
$15.5M 0.16%
1,079,700
-4,700
-0.4% -$90.4K
ELDN icon
88
Eledon Pharmaceuticals
ELDN
$262M
$14.8M 0.16%
+140,951
New +$14.4M
NTRA icon
89
Natera
NTRA
$36.4B
$13.9M 0.15%
1,276,190
– –
LUMO
90
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$13.6M 0.14%
205,111
-16,189
-7% -$2M
NBIX icon
91
Neurocrine Biosciences
NBIX
$18.3B
$13.1M 0.14%
284,841
-156,500
-35% -$7.59M
WMGIZ
92
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$12.7M 0.13%
8,679,975
+1,779,975
+26% +$2.6M
PRQR icon
93
ProQR Therapeutics
PRQR
$250M
$12M 0.13%
2,305,446
– –
AUPH icon
94
Aurinia Pharmaceuticals
AUPH
$1.95B
$11M 0.12%
1,797,400
– –
ARGX icon
95
argenx
ARGX
$55.2B
$10.6M 0.11%
+500,000
New +$10.4M
HRTX icon
96
Heron Therapeutics
HRTX
$93.4M
$9M 0.09%
650,000
– –
MNK
97
PUT
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$8.96M 0.09%
+200,000
New +$8.77M
ADAP
98
DELISTED
Adaptimmune Therapeutics
ADAP
$8.6M 0.09%
1,914,660
– –
AZN icon
99
PUT
AstraZeneca
AZN
$270B
$8.52M 0.09%
+125,000
New +$8.16M
ALKS icon
100
Alkermes
ALKS
$8.13B
$8.41M 0.09%
145,000
– –
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q2 2017 Portfolio in Review

As of Q2 2017, OrbiMed held 152 positions worth $9.54B, up 8.1% from $8.82B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

OrbiMed's Q2 2017 filing shows 15 new, 35 increased, 32 reduced and 15 closed positions. Its largest new stake was Cigna: 1,222,100 shares worth $205M. The largest sale was Centene, an estimated $118M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2017 buy was Cigna: 1,222,100 shares worth $205M.
  • OrbiMed added most to Gilead Sciences in Q2 2017, an estimated $84.7M increase.
  • OrbiMed's biggest Q2 2017 reduction was Pfizer, cutting an estimated $98M.
  • OrbiMed fully exited Centene in Q2 2017, selling an estimated $118M.
  • OrbiMed's ten largest holdings make up 35% of its $9.54B portfolio in Q2 2017.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2017.
  • OrbiMed's portfolio value rose 8.1% quarter-over-quarter to $9.54B.

Based on OrbiMed's 13F filing for Q2 2017, filed 14 Aug 2017.